Neurological Surgery Doctors in West Orange, NJ Accepting Medicare

3 Neurological Surgery doctors found. Showing 1 - 3

Otakar R Hubschmann, MD FACS Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 101 Old Short Hills Rd Ste 409, West Orange, NJ 07052 Phone: 973-322-6732    Fax: 973-322-6545

Arthur M Gilman, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 101 Old Short Hills Rd, Suite 409, West Orange, NJ 07052 Phone: 973-322-6732    Fax: 973-322-6545

Joseph M Koziol, MD FACS Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 101 Old Short Hills Rd Ste 409, West Orange, NJ 07052 Phone: 973-322-6732    Fax: 973-322-6545

News Archive

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

Viewpoints: Texas' painful budget cuts; Congress 'should' attack deficit, Medicare costs

The real problem is that liberals and conservatives alike have over the years gauged an elected official's support for the goals of a program by the money he or she has been willing to spend on it. Thus, liberals measure one's support for education, welfare and health programs by how much more one votes to fund them each year.

ECNP honors Kaj Blennow with 2010 Neuropsychopharmacology Award

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Kaj Blennow as the recipient of the 2010 ECNP Neuropsychopharmacology Award in recognition of his original and influential contributions to Alzheimer's disease research. The ECNP Neuropsychopharmacology Award is presented annually and recognises distinguished research in neuropsychopharmacology and closely related disciplines. The award is accompanied by a prize of - 20,000.

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

Biotechnology company MabCure, Inc. today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure's tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women.

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Soligenix, Inc. (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

Read more Medical News

› Verified 5 days ago